Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Cash from Operations (2023 - 2025)

Zenas BioPharma has reported Cash from Operations over the past 3 years, most recently at 52414000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 52414000.0 for Q4 2025, down 35.95% from a year ago — trailing twelve months through Dec 2025 was 172333000.0 (down 44.0% YoY), and the annual figure for FY2025 was 172333000.0, down 44.0%.
  • Cash from Operations for Q4 2025 was 52414000.0 at Zenas BioPharma, down from 41125000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for ZBIO hit a ceiling of 15400000.0 in Q4 2023 and a floor of 52414000.0 in Q4 2025.
  • Median Cash from Operations over the past 3 years was 37051000.0 (2025), compared with a mean of 34156333.33.
  • Biggest five-year swings in Cash from Operations: crashed 150.35% in 2024 and later tumbled 32.41% in 2025.
  • Zenas BioPharma's Cash from Operations stood at 15400000.0 in 2023, then plummeted by 150.35% to 38554000.0 in 2024, then crashed by 35.95% to 52414000.0 in 2025.
  • The last three reported values for Cash from Operations were 52414000.0 (Q4 2025), 41125000.0 (Q3 2025), and 41743000.0 (Q2 2025) per Business Quant data.